OKYO Company Profile and Key Details

Q: Who are the executives of OKYO?

Dr. Gary S. Jacob Ph.D.Chief Executive Officer & Executive DirectorMr. Michael Paul BeckFounderDr. Rajkumar Patil Ph.D.Chief Scientific Officer

NASDAQ : OKYO

OKYO Pharma

$1.55

-0.14-8.28%

At Close 4:00 PM

60.78

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

OKYO Pharma Limited (OKYO) stock declined over -8.28%, trading at $1.55 on NASDAQ, down from the previous close of $1.69. The stock opened at $1.66, fluctuating between $1.55 and $1.66 in the recent session.

Stock Snapshot

1.69

Prev. Close

59.47M

Market Cap

1.55

Day Low

-30.88

P/E Ratio

-0.0502

EPS (TTM)

-0.15

Cash Flow per Share

1.66

Open

38.37M

Number of Shares

1.66

Day High

66.69%

Free Float in %

N/A

Book Value

201.04K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 13, 2026	1.67	1.67	1.55	1.55	201.27K
Jul 10, 2026	1.70	1.73	1.65	1.69	78.09K
Jul 09, 2026	1.68	1.69	1.63	1.68	78.85K
Jul 08, 2026	1.67	1.85	1.63	1.66	689.4K
Jul 07, 2026	1.59	1.75	1.58	1.75	112.67K
Jul 06, 2026	1.57	1.62	1.57	1.61	7.26K
Jul 02, 2026	1.48	1.60	1.48	1.57	125.85K
Jul 01, 2026	1.48	1.54	1.47	1.50	41.11K
Jun 30, 2026	1.51	1.57	1.46	1.50	112.47K
Jun 29, 2026	1.51	1.57	1.51	1.52	34.37K
Jun 26, 2026	1.54	1.59	1.54	1.55	47.25K
Jun 25, 2026	1.55	1.61	1.53	1.54	87.19K
Jun 24, 2026	1.58	1.65	1.55	1.55	59.55K
Jun 23, 2026	1.54	1.64	1.54	1.58	69.47K
Jun 22, 2026	1.57	1.60	1.54	1.57	53.78K
Jun 18, 2026	1.57	1.60	1.56	1.59	65.09K
Jun 17, 2026	1.50	1.60	1.50	1.57	75.48K
Jun 16, 2026	1.57	1.57	1.45	1.50	47.46K
Jun 15, 2026	1.52	1.55	1.47	1.52	79.79K
Jun 12, 2026	1.56	1.56	1.42	1.52	157.15K

Contact Details

London, GL W1K 1NA

United Kingdom

https://www.okyopharma.com 442 074 952379

About Company

OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK.

Stock Peers

ARGX

-1.37-0.16%

argenx SE$876.25 REGN

-1.43-0.22%

Regeneron Pharmaceuticals, Inc.$663.09 UTHR

-11.49-2.10%

United Therapeutics Corporation$535.57 MDGL

-5.7-1.06%

Madrigal Pharmaceuticals, Inc.$531.00 VRTX

-5.14-1.06%

Vertex Pharmaceuticals Incorporated$480.25 KRYS

-2.37-0.65%

Krystal Biotech, Inc.$363.44 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-10.43-3.21%

Praxis Precision Medicines, Inc.$314.56 LGND

-6.99-2.21%

Ligand Pharmaceuticals Incorporated$309.25 ONC

5.26001+1.76%

BeOne Medicines AG$303.96

Company Overview

OKYO Pharma Limited (NASDAQ:OKYO) closed at $1.55 USD, losing -$0.14 (-8.28%) from the previous close of $1.69. The stock is currently mid-range between its 52-week high and low $1.42 and $3.35. With a market capitalization of about $59.47 million, OKYO Pharma Limited is classified as a micro-cap and shows lower-than-market volatility (beta ~0.04). Key stats such as the average daily volume over the past year has been around 73.81 thousand shares, trading with heavier-than-usual volume. Headquartered in London, GL, OKYO Pharma Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO Robert J. Dempsey, the company employs approximately 4 people and listed since May 17, 2022. OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort.

Frequently Asked Questions

What is the current OKYO Pharma Limited (OKYO) stock price?

OKYO Pharma Limited (NASDAQ: OKYO) stock price is $1.55 in the last trading session. During the trading session, OKYO stock reached the peak price of $1.66 while $1.55 was the lowest point it dropped to. The percentage change in OKYO stock occurred in the recent session was -8.28% while the dollar amount for the price change in OKYO stock was - $0.14.

OKYO's industry and sector of operation?

The NASDAQ listed OKYO is part of Biotechnology industry that operates in the broader Healthcare sector. OKYO Pharma Limited designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of OKYO?

Dr. Gary S. Jacob Ph.D.
Chief Executive Officer & Executive Director
Mr. Michael Paul Beck
Founder
Dr. Rajkumar Patil Ph.D.
Chief Scientific Officer

How OKYO did perform over past 52-week?

OKYO's closing price is 9.15% higher than its 52-week low of $1.42 where as its distance from 52-week high of $3.35 is -53.72%.

How many employees does OKYO have?

Number of OKYO employees currently stands at 4.

Link for OKYO official website?

Official Website of OKYO is: https://www.okyopharma.com

How do I contact OKYO?

OKYO could be contacted at phone 442 074 952379 and can also be accessed through its website. OKYO operates from 55 Park Lane, London, GL W1K 1NA, United Kingdom.

How many shares of OKYO are traded daily?

OKYO stock volume for the day was 201.04K shares. The average number of OKYO shares traded daily for last 3 months was 73.81K.

What is the market cap of OKYO currently?

The market value of OKYO currently stands at $59.47M with its latest stock price at $1.55 and 38.37M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Price Chart

Stock Price Today

Stock Snapshot

1.69

Prev. Close

59.47M

Market Cap

1.55

Day Low

-30.88

P/E Ratio

-0.0502

EPS (TTM)

-0.15

Cash Flow per Share

1.66

Open

38.37M

Number of Shares

1.66

Day High

66.69%

Free Float in %

N/A

Book Value

201.04K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jul 13, 2026	1.67	1.67	1.55	1.55	201.27K
Jul 10, 2026	1.70	1.73	1.65	1.69	78.09K
Jul 09, 2026	1.68	1.69	1.63	1.68	78.85K
Jul 08, 2026	1.67	1.85	1.63	1.66	689.4K
Jul 07, 2026	1.59	1.75	1.58	1.75	112.67K
Jul 06, 2026	1.57	1.62	1.57	1.61	7.26K
Jul 02, 2026	1.48	1.60	1.48	1.57	125.85K
Jul 01, 2026	1.48	1.54	1.47	1.50	41.11K
Jun 30, 2026	1.51	1.57	1.46	1.50	112.47K
Jun 29, 2026	1.51	1.57	1.51	1.52	34.37K
Jun 26, 2026	1.54	1.59	1.54	1.55	47.25K
Jun 25, 2026	1.55	1.61	1.53	1.54	87.19K
Jun 24, 2026	1.58	1.65	1.55	1.55	59.55K
Jun 23, 2026	1.54	1.64	1.54	1.58	69.47K
Jun 22, 2026	1.57	1.60	1.54	1.57	53.78K
Jun 18, 2026	1.57	1.60	1.56	1.59	65.09K
Jun 17, 2026	1.50	1.60	1.50	1.57	75.48K
Jun 16, 2026	1.57	1.57	1.45	1.50	47.46K
Jun 15, 2026	1.52	1.55	1.47	1.52	79.79K
Jun 12, 2026	1.56	1.56	1.42	1.52	157.15K

Contact Details

London, GL W1K 1NA

United Kingdom

https://www.okyopharma.com 442 074 952379

About Company

Stock Peers

ARGX

-1.37-0.16%

argenx SE$876.25 REGN

-1.43-0.22%

Regeneron Pharmaceuticals, Inc.$663.09 UTHR

-11.49-2.10%

United Therapeutics Corporation$535.57 MDGL

-5.7-1.06%

Madrigal Pharmaceuticals, Inc.$531.00 VRTX

-5.14-1.06%

Vertex Pharmaceuticals Incorporated$480.25 KRYS

-2.37-0.65%

Krystal Biotech, Inc.$363.44 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

-10.43-3.21%

Praxis Precision Medicines, Inc.$314.56 LGND

-6.99-2.21%

Ligand Pharmaceuticals Incorporated$309.25 ONC

5.26001+1.76%

BeOne Medicines AG$303.96

Company Overview

Technical Performance

Short-term trend indicators are bullishly aligned (SMA20 -8.95%, SMA50 -17.45%, SMA200 -23.64%). The stock’s 14-day RSI is 40.61 (neutral), while the ATR of 0.22 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -48.64% below its high and over 66.99% above its low. Average 10-day trading volume of 194.59 thousand shares is significantly above the 3-month average of 77.17 thousand, indicating heightened recent market interest.

Valuation Metrics

OKYO Pharma Limited trades at a P/E ratio of -14.55, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of -17.42 indicating negative book value, which may reflect financial stress. The P/FCF stands at -19.68, also below market averages.

Dividend & Fair Value

OKYO Pharma Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.04. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

OKYO Pharma Limited generated EPS of -$0.13 over the past year. Five-year average earnings growth is -114.91%. The latest quarter delivered EPS of -$0.04. The next quarter is forecast at -$0.05. Next year's EPS is expected at $0.00. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 3 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $7.00 to $5.00. The high target offers 351.61% upside. The low target suggests 222.58% downside. The mean target is $6.00. This offers 287.1% upside. OKYO Pharma Limited earnings surprise history is a mixed track record. The quarter that ended June 03, 2026, missed forecasts by -49.75%. The prior quarter beat by -85.71%. Over the last six quarters, Apple has recorded several small beats. These include 45.56% in July 18, 2025.

Shareholding & Insider Activity

OKYO Pharma Limited has 37.61 million shares outstanding. The public float is 25.08 million shares, elevated short interest at 0.28% of float. This equals 77.25 thousand shares. The short ratio is 0.56 days. Institutional investors hold 11.05% of the float. Insiders own 33.31%. CERRONE GABRIELE M holds 62.50 thousand shares, BRANCACCIO JOHN P has 16.67 thousand shares and JACOB GARY S has 12.50 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, OKYO Pharma has not generated any revenue. Returns are negative, with ROA at -127.98% and ROE at 84.80%.
On valuation metrics, OKYO Pharma trades at a P/E of -14.55, P/S of 0.00 and P/B of -17.42. Liquidity is tight, with a current ratio of 0.58 and quick ratio of 0.58. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -1193858.59 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is -0.05, supported by a cash flow-to-debt ratio of -16.68.

Quarterly Financial Highlights

For the quarter ended Mar 31, 2025, OKYO Pharma posted revenue of $0.00, down slightly from $0.00 in the prior quarter. Gross profit was - $2.56K (margin 0.00%). Operating income was - $7.19M (margin 0.0%). Net income was- $4.71M (EPS - $0.12).
The company ended the quarter with $1.56M in cash and short-term investments, a total debt of $0.00, and net debt of - $1.56M. Total assets were $3.68M, with equity of - $5.55M. Financials further reflected weakness, with operating cash flow of - $1.81M, free cash flow of - $1.81M, and capital expenditures of - $1.21K.

Price Forecast & Outlook

Our AI price prediction model suggests that OKYO Pharma Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 7.1%, with price expected at $1.66 by July 27, 2026, within a range of $1.59 to $1.73 3-Month Outlook: Projected fall of -65.81%, reaching $0.53 by October 08, 2026, with a range of $0.47 to $0.60. 1-Year Outlook: Projected gain of 62.58%, with price at $2.52 by July 13, 2027, within a range of $0.00 to $1.15.

Key Takeaways

OKYO Pharma Limited (NASDAQ:OKYO) shares are flat 3.86% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows OKYO Pharma Limited trading at a premium to the broader market with a P/E of -14.55. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $6.64, suggesting 328.39% upside. Our AI forecast model points to short-term strength (7.1% over two weeks), a medium-term fall (-65.81% over three months), and a longer-term gain (62.58% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current OKYO Pharma Limited (OKYO) stock price?

OKYO's industry and sector of operation?

Who are the executives of OKYO?

Dr. Gary S. Jacob Ph.D.
Chief Executive Officer & Executive Director
Mr. Michael Paul Beck
Founder
Dr. Rajkumar Patil Ph.D.
Chief Scientific Officer

How OKYO did perform over past 52-week?

OKYO's closing price is 9.15% higher than its 52-week low of $1.42 where as its distance from 52-week high of $3.35 is -53.72%.

How many employees does OKYO have?

Number of OKYO employees currently stands at 4.

Link for OKYO official website?

Official Website of OKYO is: https://www.okyopharma.com

How do I contact OKYO?

OKYO could be contacted at phone 442 074 952379 and can also be accessed through its website. OKYO operates from 55 Park Lane, London, GL W1K 1NA, United Kingdom.

How many shares of OKYO are traded daily?

OKYO stock volume for the day was 201.04K shares. The average number of OKYO shares traded daily for last 3 months was 73.81K.

What is the market cap of OKYO currently?

The market value of OKYO currently stands at $59.47M with its latest stock price at $1.55 and 38.37M of its shares outstanding.

Employees	4
Beta	0.04
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	March
Sector	Healthcare
Industry	Biotechnology

Employees	4
Beta	0.04
Sales or Revenue	$0.00
5Y Sales Change%	0%
Fiscal Year Ends	March
Sector	Healthcare
Industry	Biotechnology

OKYO Company Profile and Key Details

OKYO Pharma

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Dividend & Fair Value

Valuation Metrics

Earnings & Analyst Outlook

Shareholding & Insider Activity

Key Takeaways

Price Forecast & Outlook

Financial & Profitability Overview

Quarterly Financial Highlights